TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
|
|
- Kristina Fox
- 5 years ago
- Views:
Transcription
1 TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting : AbbVie, Amgen, Radius, Sanofi
2 TREATING OSTEOPOROSIS IN 2017: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Denosumab Long-term data Withdrawal New drugs Abaloparatide Romosozumab
3 Watts NB Osteoporos Int 2017;28:
4 DENOSUMAB (PROLIA ) INHIBITOR OF RANK LIGAND RANKL* Produced by osteocytes, stromal cells and osteoblasts Binds with RANK (receptor) which is expressed on the surface of osteoclast precursors, differentiated and active osteoclasts Denosumab is a human monoclonal antibody that ties up RANKL, preventing binding with its receptor, decreasing osteoclast development, function and survival Given as a subcutaneous injection, 60 mg SQ twice yearly *RANKL = ligand to receptor activator Boyle WJ et al Nature 2003;423: of nuclear factor kappa B Bekker PJ et al J Bone Miner Res 2004;19: Cummings SR et al N Engl J Med 2009;361: Prolia Package Insert
5 DENOSUMAB PHARMACODYNAMICS McClung MR et al N Engl J Med 2006;354:
6 Subjects with New Fractures (%) DENOSUMAB FREEDOM TRIAL 3-YEAR FRACTURE RESULTS ,808 postmenopausal women with osteoporosis 68% 20% Placebo Denosumab 40% Vertebral Non-Vert Hip Cummings SR et al N Engl J Med 2009;361:
7 Percentage Change from Baseline Prepared by Nelson Watts MD YEAR BMD CHANGE WITH DENOSUMAB Lumbar spine Total hip 21.7% % Bone HG et al Lancet Diabet Endocrinol 2017;5:
8 FRACTURES AFER TEN YEARS OF DENOSUMAB Bone HG et al Lancet Diabet Endocrinol 2017;5:
9 Median ng/ml (Q1, Q3) BTM AFTER DISCONTINUING DENOSUMAB PHASE 2 STUDY IN WOMEN WITH LOW BMD Serum CTx Discontinued Placebo Treatment 210 mg Q6M Open-label alendronate * * *P < at month 36 and = 0.05 at month 48 vs placebo. P = at month 36 vs placebo. Months Miller PD et al Bone 2008;43:222-29
10 % Change (LS mean ± SE) BMD CHANGE AFTER STOPPING DENOSUMAB 12 Lumbar Spine BMD All discontinued All discontinued at 36 months Subjects who rec d 30 mg q 3 mos were given 60 mg q 6 mos starting at Month 36 Months Miller PD et al Bone 2008;43:
11 DISCONTINUING DENOSUMAB AFTER 8 YEARS CHANGES IN BMD Year 8 Year Lumbar Spine Lumbar Spine Femoral Neck McClung MR et al Osteoporos Int 2017;28:
12 DENOSUMAB MECHANISM OF ACTION Osteoclast precursors and RANKL are still there and ready to go after denosumab is gone Over.jpg#id=8&iurl=http%3A%2F%2Fimage.slidesharecdn.com%2Fosteoporosis-pathophysiology-and-management-dr-frank2181%2F95%2Fosteoporosispathophysiology-and-management-dr-frank jpg&action=click
13 IS THE RISK FOR NON-VERTEBRAL FRACTURES INCREASED AFTER STOPPING D MAB? 797 subjects d/c study drug in FREEDOM after 2-5 doses (470 placebo, 327 d mab) Other OP Rx begun by 42% former placebo and 28% of former d mab subjects New fractures 9% placebo (13.5 per 100 subject years) 7% denosumab (9.7 per 100 subject years) HR* 0.82 (CI 0.49, 1.38) Short off-treatment period (mean 0.8 mos); effect manifest after longer off-treatment period cannot be excluded *HR adjusted for age and total hip BMD T-score at baseline Brown JP et al J Bone Miner Res 2013;28:746-52
14 VERTEBRAL FRACTURES AFTER DISCONTINUING DENOSUMAB OR PLACEBO IN FREEDOM STUDY Vertebral fractures in patients who discontinued either placebo or denosumab in the FREEDOM study or who stopped denosumab in the FREEDOM Extension study and who had a follow-up at least 7 months after their last dose Vertebral fractures Multiple vertebral fractures On study drug Off study drug Cummings SR et al ASBMR 2016
15 Published online 28 October 2015
16 Published online 28 October 2015
17 Published online 28 October 2015
18 Published online 28 October 2015
19 J Clin Endocrinol Metab 2017;102:
20 J Clin Endocrinol Metab 2017;102:
21 J Clin Endocrinol Metab 2017;102: Athanasios D Anastasilakis, 1 Sterghios A Polyzos, 2 Polyzois Makras, 3 Berengere Aubry-Rozier, 4 Stella Kaori, 5 and Olivier Lamy 4
22 Anastasilakis AD et al J Bone Miner Res 2017;32:
23 MULTIPLE VERTEBRAL FRACTURES AFTER DISCONTINUATION OF D MAB 112 fractures in 24 women 92% with >1 fracture 8-16 months after last dose of d mab Anastasilakis AD et al J Bone Miner Res 2017;32:
24 Prolia PI accessed 04/21/2017
25 McClung MR et al Osteoporos Int 2017;28:
26 BMD LOSS AFTER STOPPING D MAB ALN 7 1 ALN => RIS, d/c due to cost 1 ALN => IBAN Dmab 5 RIS 4 IBAN 2 IBAN => TPTD TPTD 2 8 stopped, 5 attributed to AE McClung MR et al Osteoporos Int.2017;28:
27 TRANSITION STUDIES ORAL BISPHOSPHONATE TO DENOSUMAB n = 1. Prior ALN 2. Prior ALN 3.Suboptimal BP 4. Oral to IV/SQ ALN 251 DMAB 253 RIS 435 DMAB 435 IBAN 416 DMAB 417 ZOL 322 DMAB 321 Age YSM Spine FN TH Prior BP (mos) Kendler DL et al J Bone Miner Res 2010;25: Roux C et al Bone 2014;58: Recknor C et al Obstet Gynecol 2013;121: Miller PD et al J Clin Endocrinol Metab 2016;101:
28 BMD percent change from baseline TRANSITION STUDIES ORAL BISPHOSPHONATE TO DENOSUMAB Lumbar Spine 5.0 DMAB 4.0 DMAB DMAB DMAB 3.0 ALN RIS 2.0 IBAN ZOL Kendler DL et al J Bone Miner Res 2010;25: Roux C et al Bone 2014;58: Recknor C et al Obstet Gynecol 2013;121: Miller PD et al J Clin Endocrinol Metab 2016;101:
29 SEQUENTIAL OR CONCOMITANT COMBINATIONS DENOSUMAB AND TERIPARATIDE ` Years 1-2 Years 3-4 Combination Denosumab Teriparatide Denosumab Denosumab Teriparatide Leder B et al Lancet 2015;336:1147
30 SEQUENTIAL OR CONCOMITANT COMBINATIONS DENOSUMAB AND TERIPARATIDE ` Years 1-2 Years 3-4 Combination Denosumab Teriparatide Denosumab Denosumab Teriparatide Leder B et al Lancet 2015;336:1147
31 SEQUENTIAL OR CONCOMITANT COMBINATIONS DENOSUMAB AND TERIPARATIDE Years 1-2 Years 3-4 Combination Denosumab Teriparatide Denosumab Denosumab Teriparatide Leder B et al Lancet 2015;336:
32 Percent Change From Baseline DENOSUMAB AND ALENDRONATE DENOSUMAB/ALENDRONATE PREFERENCE STUDY (DAPS) Switching from denosumab to alendronate, bone loss did not occur 8 6 Denosumab (n=126) Alendronate (N=115) Lumbar spine 4 2 Total hip Months Based on data from Freemantle N et al Osteoporos Int 2012;23:317-26
33 BMD LOSS AFTER STOPPING D MAB What about zoledronic acid after stopping d mab? Timing is critical bone turnover must be high enough to provide active remodeling sites for bisphosphonates to bind.
34 Management of osteoporosis is a longterm proposition, similar to treatment of hypertension or hypercholesterolemia
35 DENOSUMAB (PROLIA ) SUMMARY In a 3-year placebo-controlled double-blind trial, denosumab was well tolerated and reduced the risk of vertebral (68%), hip (40%) and nonvertebral (20%) fractures After 10 years of treatment, average BMD gains were 22% in the spine and 9% in the femoral neck and total hip In the 7-year extension, ONJ (5.2 per 10,000 person years) and AFF (0.8 per 10,000 person years) were uncommon Patients may be at risk of multiple vertebral fractures if denosumab is discontinued Based on limited data, treatment most likely to be effective if denosumab is stopped is an oral bisphosphonate Cummings SR et al N Engl J Med 2009;361: Papapoulos S et al, ASBMR 2016 Prolia Package Insert
36 TREATING OSTEOPOROSIS IN 2017: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Denosumab Long-term data Withdrawal New drugs Abaloparatide (approved 04/2017) Romosozumab (still under FDA evaluation)
37 FDA-APPROVED MEDICATIONS INDICATIONS Postmenopausal Osteoporosis Glucocorticoid-induced Osteoporosis Men Drug Prevention Treatment Prevention Treatment Estrogen Calcitonin (Miacalcin, Fortical ) Raloxifene (Evista ) Ibandronate (Boniva ) Alendronate (Fosamax ) Risedronate (Actonel ) Risedronate (Atelvia ) Zoledronate (Reclast ) Denosumab (Prolia ) Teriparatide (Forteo ) ` Abaloparatide (Tymlos )
38 TREATMENT OF OSTEOPOROSIS Antiresorptive Agents Calcitonin Raloxifene Alendronate Risedronate Ibandronate Zoledronate Denosumab Anabolic Agents Teriparatide Abaloparatide
39 FDA-APPROVED MEDICATIONS EVIDENCE FOR FRACTURE REDUCTION Drug Vertebral Fracture Nonvertebral Fracture Hip Fracture Calcitonin (Miacalcin, Fortical ) No effect demonstrated No effect demonstrated Raloxifene (Evista ) No effect demonstrated No effect demonstrated Ibandronate (Boniva ) No effect demonstrated No effect demonstrated Alendronate (Fosamax ) Risedronate (Actonel, Atelvia ) Zoledronic acid (Reclast ) Denosumab (Prolia ) Teriparatide (Forteo ) Abaloparatide (Tymlos ) No effect demonstrated No effect demonstrated Evidence for effect but not an FDA-approved indication
40 ABALOPARATIDE (TYMLOS ) PTHrP ANALOG Distinct from PTH but same rat findings and warnings regarding osteosarcoma Daily SQ injection (80 mcg) for no longer than 2 years Compared with teriparatide Increases in BMD are greater and faster, esp. at the hip Fracture reduction is at least as good, maybe better Less hypercalcemia Cartridge contains a 30 day supply Does not require refrigeration Transdermal delivery patch currently in Phase 2 trials
41 ANALOG OF HUMAN PTHrP 1-34 hpth 1-34 hpthrp 1-34 PTHrP analog (abaloparatide) % hpthrp 38% hpthrp Functional optimization of abaloparatide based on amino acids Hattersley R et al ENDO 2012 OR08-1
42 ABALOPARATIDE PHASE 3 TRIAL 18 Miller PD et al JAMA 2016;316:
43 BONE TURNOVER MARKERS ABALOPARATIDE vs TERIPARATIDE Miller PD et al JAMA 2016;316:
44 ABALOPARATIDE vs TERIPARATIDE 18-MONTH TRIAL *p< % 78% Miller PD et al JAMA 2016;316:
45 ABALOPARATIDE vs TERIPARATIDE 18-MONTH STUDY: EFFECT ON FRACTURES Nonvert Fx Clinical Fx Major OP fx Teriparatide 28% 29% 55% Abaloparatide 43%* 45%* 70%* + *Significantly different from placebo + Significantly different from teriparatide Miller PD et al JAMA 2016;316:
46 ABALOPARATIDE EFFECT ON NONVERTEBRAL FRACTURES 28% 43% ABAL vs PBO < 0.05 TPTD vs PBO = NS ABAL vs TPTD = NS Miller PD et al JAMA 2016;316:
47 ABALOPARATIDE PHASE 3 TRIAL EXTENSION (ACTIVExtend) Alendronate 70 mg Weekly Alendronate 70 mg Weekly 43 Bone H et al ASBMR 2017
48 ABALOPARATIDE PHASE 3 TRIAL EXTENSION (ACTIVExtend) New Vertebral Fractures Nonvertebral Fractures Bone H et al ASBMR 2017
49 ABALOPARATIDE (TYMLOS ) TRANSDERMAL DELIVERY DEVICE Solid Microstructured Transdermal System (smts) Painless, needle-free administration through skin 5 minute wear time Rapid drug release, peak similar to SQ
50 SCLEROSTIN Produced by osteocytes 1 Inhibits the anabolic Wnt signaling pathway 2 Deficiency results in a sclerosing bone disease (sclerosteosis) 3 1. Van Bezooijen J Bone Miner Res. 2005;20 (Suppl 1):S9 2. Warmington K et al. J Bone Miner Res. 2005;20(Suppl 1):S22 3. Gardner JC et al. J Clin Endocrinol Metab E-pub. Sep 27
51 Wnt SIGNALING PATHWAY Wnt Axin APC Β-catenin L R P CKIα Frizzled Dsh GSK3β Mesenchymal Stem Cell (MSC) Osteoprogenitor Cell Pre-Osteoblast Β-catenin Β-catenin TCF target genes activated
52 SCLEROSTIN INHIBITS THE Wnt SIGNALING PATHWAY Wnt Osteocyte Sclerostin L R P Frizzled Mesenchymal Stem Cell (MSC) APC Axin CKIα Dsh Osteoprogenitor Cell P P P P Β-catenin Β-catenin GSK3β Β-catenin Pre-Osteoblast Groucho CBP TCF target genes activated repressed
53 ANTIBODY TO SCLEROSTIN RELEASES THE Wnt SIGNALING PATHWAY Sclerostin Wnt Axin APC Β-catenin L R P CKIα Frizzled Dsh GSK3β Mesenchymal Stem Cell (MSC) Osteoprogenitor Cell Pre-Osteoblast Β-catenin Β-catenin TCF target genes activated Stimulation of formation without increasing resorption?
54 A NEW ANABOLIC APPROACH: BLOCK AN INHIBITOR OF BONE FORMATION Romosozumab (EVENITY ), an antibody to sclerostin, restores bone mass in rats and monkeys 1,2 Phase 2 study in humans 3 Early, marked, but transient increase in markers of bone formation Modest, persistent reduction in bone resorption Substantial increase in BMD in the spine and hip Two Phase 3 studies 4,5 1. Warmington K et al J Bone Miner Res. 2005;20(Suppl 1):S22 2. Ominsky M et al J Bone Miner Res. 2006;21(Suppl 1):S44 3. McClung MR et al, N Engl J Med Cosman F et al N Engl J Med 2016;375: Saag KG et al N Engl J Med :2017;377:
55 FRAME STUDY PHASE 3 TRIAL WITH ROMOSOZUMAB (EVENITY ) 7180 subjects; romosozumab dose 210 mg SQ monthly Placebo Year 1 Romo* Year 1 D mab Year 2 D mab Year 2 Cosman F et al N Engl J Med 2016;375:
56 FRAME STUDY PHASE 3 TRIAL WITH ROMOSOZUMAB (EVENITY ) 7180 subjects; romosozumab dose 210 mg SQ monthly Placebo Year 1 Romo* Year 1 D mab Year 2 D mab Year 2 Cosman F et al N Engl J Med 2016;375:
57 FRAME STUDY PHASE 3 TRIAL WITH ROMOSOZUMAB (EVENITY ) 7180 subjects; romosozumab dose 210 mg SQ monthly Placebo Year 1 Romo* Year 1 D mab Year 2 D mab Year 2 Cosman F et al N Engl J Med 2016;375:
58 ANTIBODY TO SCLEROSTIN BLOCKS AN INHIBITOR OF BONE FORMATION ROMOSOZUMAB (EVENITY ) FRAME, 2-year trial, n= Placebo Year 1 Romo* Year 1 D mab Year 2 D mab Year 2 ARCH, 2-year trial, n= Alendronate Year 1 Alendronate Year 2 Romo* Year 1 Alendronate Year 2 *Romosuzumab 210 mg SQ monthly 1. Cosman F et al N Engl J Med 2016;375: Saag KG et al N Engl J Med :2017;377:
59 ANTIBODY TO SCLEROSTIN BLOCKS AN INHIBITOR OF BONE FORMATION ROMOSOZUMAB (EVENITY ) FRAME, 2-year trial, n= VFX Clin Fx nvfx Year 1 (ROMO vs PLBO) 73%* 36%* 25% Year 2 (D MAB for all) 75%* 33%* 25% *p< Cosman F et al N Engl J Med 2016;375:
60 ANTIBODY TO SCLEROSTIN BLOCKS AN INHIBITOR OF BONE FORMATION ROMOSOZUMAB (EVENITY ) FRAME, 2-year trial, n= VFX Clin Fx nvfx Year 1 (ROMO vs PLBO) 73%* 36%* 25% Year 2 (D MAB for all) 75%* 33%* 25% ARCH, 2-year trial, n= VFX Clin Fx NVFx Hip fx Year 1 (ROMO vs ALN) 37%* 28%* 26% 36% Year 2 (ALN for all) 48%* 27%* 19%* 38%* *p< Cosman F et al N Engl J Med 2016;375: Saag KG et al N Engl J Med :2017;377:
61 SAFETY FINDINGS WITH ROMOSOZUMAB FRAME Study (ROMO vs PLBO followed by d mab for all) 1 Months 0-12 (romosozumab vs placebo) Injection site reactions 5.25% romo vs 2.9% placebo AEs >10%: arthralgia, nasopharyngitis, back pain No difference in hearing loss or knee OA ONJ: 1 case after 12 mos of romo, 1 after 12 mos romo then 1 dose of dmab AFF: 1 case after 3 mos of romo Hypersensitivity SAE: 7 patients receiving ROMO 1. Cosman F et al N Engl J Med 2016;375:
62 SAFETY FINDINGS WITH ROMOSOZUMAB FRAME Study (ROMO vs PLBO followed by d mab for all) 1 Months 0-12 (romosozumab vs placebo) Injection site reactions 5.25% romo vs 2.9% placebo AEs >10%: arthralgia, nasopharyngitis, back pain No difference in hearing loss or knee OA ONJ: 1 case after 12 mos of romo, 1 after 12 mos romo then 1 dose of dmab AFF: 1 case after 3 mos of romo Hypersensitivity SAE: 7 patients receiving ROMO ARCH Study (ROMO vs ALN followed by ALN for all) 2 6 AFF (4 with ALN alone, 2 with romo followed by ALN) 2 ONJ (1 with ALN alone, 1 with romo followed by ALN) 1. Cosman F et al N Engl J Med 2016;375: Saag KG et al N Engl J Med :2017;377:
63 SAFETY FINDINGS WITH ROMOSOZUMAB FRAME Study (ROMO vs PLBO followed by d mab for all) 1 Months 0-12 (romosozumab vs placebo) Injection site reactions 5.25% romo vs 2.9% placebo AEs >10%: arthralgia, nasopharyngitis, back pain No difference in hearing loss or knee OA ONJ: 1 case after 12 mos of romo, 1 after 12 mos romo then 1 dose of dmab AFF: 1 case after 3 mos of romo Hypersensitivity SAE: 7 patients receiving ROMO ARCH Study (ROMO vs ALN followed by ALN for all) 2 6 AFF (4 with ALN alone, 2 with romo followed by ALN) 2 ONJ (1 with ALN alone, 1 with romo followed by ALN) Cardiovascular SAEs: 2.5% romo, 1.9% ALN 1. Cosman F et al N Engl J Med 2016;375: Saag KG et al N Engl J Med :2017;377:
64 SELECTING AMONG THERAPEUTIC AGENTS Efficacy broad spectrum antifracture efficacy (alendronate, risedronate, zoledronate, denosumab) Route of administration oral (fasting or with food) or parenteral Frequency of administration daily, weekly, monthly, quarterly, twice yearly, once yearly Side effects/tolerability depends on agent and patient Long-term BMD gains, help with fracture healing Non-skeletal effects breast cancer reduction (raloxifene) Cost/insurance coverage Watts NB, personal opinion
65 SPECTRUM OF FRACTURE RISK Teriparatide Abaloparatide?Romosozumab Denosumab Bisphosphonate No need for pharmacologic treatment Watts NB, personal opinion
66 TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Denosumab Long-term data Withdrawal New drugs Abaloparatide Romosozumab
67 Questions or comments?
2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationTREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationOsteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic
Osteoporosis 2017 Breaking News Julie L. Carkin, MD The Seattle Arthritis Clinic 1 Yes, Hopefully & No Anabolic Teriparatide Abaloparatide Romosozumab blosozumab Anti-catabolic Bisphosphonates Denosumab
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More information7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation
New Osteoporosis Treatments Disclosures Mary L. Bouxsein, PhD Department of Orthopedic Surgery Harvard Medical School, Boston, MA Advisory Board: Research funding: Merck, Eli Lilly, Radius Merck, Amgen
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationReducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts.
Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians Please complete the preassessment before the session starts. Sponsorship and Support This educational activity is jointly
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationSummary. Treatment. a larger extent than predicted. spine much faster and to. that fracture protection is greater
The Future of Ost eoporosis Care in Research and Practice ACOI Luncheon October 26, 2010 Steven T Harris MD FACP Clinical i l Profess sor of fmedicine i University of California, San Francisco Treatment
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationAACE. Osteoporosis Treatment: Then and Now
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationDisclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?
Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E.
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationRheumatology. keeping Joints in Motion. Treating and Preventing Fractures
Rheumatology keeping Joints in Motion Treating and Preventing Fractures Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA, Los Angeles CA Private practice, Tustin
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010
OSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010 Alessandria, 5 giugno 2010 Novità nel trattamento dell osteoporosi Stefania Boldini Francesco Bertoldo Dipartimento di
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationA KL/R / AN A K/O / P O G G
Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition
More informationClinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
SHORT REPORT JBMR Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases Athanasios D Anastasilakis, 1 Stergios
More information9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationOsteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center
Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Osteoporosis in Men: An Update on the Epidemiology, Clinical Evaluation Current Treatments and Treatments in Development Learning
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationHow long to treat? Disclosure. What is the real problem? Conclusions
Disclosure How long to treat? 11 th Annual Update on Osteoporosis and Skeletal Health Institutional Grant / Research Support Amgen, Eli Lilly, Merck Consulting / Speaking Amgen, Eli Lilly, Merck, Radius
More informationOsteoporosis Medications: A Case-Based Discussion. Laila S. Tabatabai, MD August 5, 2017
Osteoporosis Medications: A Case-Based Discussion Laila S. Tabatabai, MD August 5, 2017 Disclosures Eli Lilly Radius Objectives Determine which patients with low bone density require treatment, along with
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationOsteoporosis TreatmentUpdate November 2018
Osteoporosis TreatmentUpdate November 2018 Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures Opinions are those of the speaker
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationDisclosures. Osteoporosis and Fracture Prevention. Objectives. Objectives. Osteoporosis Overview. Advisory Board: Hologic Advisory Board: LabCorp
Disclosures Osteoporosis and Fracture Prevention Advisory Board: Hologic Advisory Board: LabCorp Nancy R. Berman MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner/Colposcopist Certified Menopause Practitioner
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationOsteoporosis: A Review of Treatment Options
Kristie N. Tu, PharmD, BCPS, CGP; Janette D. Lie, PharmD, BCACP; Chew King Victoria Wan, PharmD Candidate; Madison Cameron, PharmD Candidate; Alaina G. Austel, PharmD Candidate; Jenny K. Nguyen, PharmD
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationBone Health Update Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh
Bone Health Update 2018 Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh The Problem 50% women and 20% of men have an osteoporotic fracture after age 50 2 million fractures annually
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationDrugs Approved for Prevention and Treatment of Postmenopausal Osteoporosis
Other Treatments of Osteoporosis- Who Should Get Bisphosphonates David Slovik, M.D. Endocrine Unit Newton-Wellesley Hospital Massachusetts General Hospital Harvard Medical School Massachusetts Medical
More informationNEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN
NEW HORIZONS IN OSTEOPOROSIS THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. Investigator-initiated grant Merck No non-fda approved recommendations RISK ASSESSMENT
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationPage 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis
More informationUpdate in Osteoporosis: Disclosures. Topics
Update in Osteoporosis: 21 Michael Maricic, M.D. Catalina Pointe Rheumatogy Clinical Associate Professor of Medicine University of Arizona Disclosures Speakers Bureau, Consultant or Clinical Research Grant
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationWhat is Osteoporosis?
What is Osteoporosis? Systemic skeletal disease characterized by: low bone mass (T-score < -2.5) biochemically normal bone microarchitectural deterioration of bone tissue Hallmark- Increased bone fragility
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationConflict of Interest Jonathan D. Adachi
Conflict of Interest Jonathan D. Adachi Consultant/Speaker Actavis Amgen Eli Lilly Merck Clinical Trials Amgen Eli Lilly Merck Novartis Stock None to declare Current Controversies In Osteoporosis Provided
More informationBisphosphonates. Making intelligent drug choices
Making intelligent drug choices Bisphosphonates are a first choice for treating osteoporosis, according to Kedrin E. Van Steenwyk, DO, an obstetrician/gynecologist at Sycamore Women s Center, Miamisburg,
More informationTreatment of Osteoporosis: Unmet Needs and Emerging Solutions
J Bone Metab 2018;25(3):133-140 https://doi.org/10.11005/jbm.2018.25.3.133 pissn 2287-6375 eissn 2287-7029 Review Article Treatment of Osteoporosis: Unmet Needs and Emerging Solutions Bente Lomholt Langdahl,
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationEmerging Challenges in Primary Care: Osteoporosis and Fracture Prevention Strategies
Emerging Challenges in Primary Care: 2017 Osteoporosis and Fracture Prevention Strategies Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner Millennium
More informationEmerging Challenges in Primary Care: Osteoporosis and Fracture Prevention Strategies. Faculty. Disclosures. [Insert Lecture Name Here]
Emerging Challenges in Primary Care: 2017 Osteoporosis and Fracture Prevention Strategies Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner Millennium
More informationFocusing on the Patient: Diagnosis and Management of Osteoporosis
Focusing on the Patient: Diagnosis and Management of Osteoporosis Learning Objectives After participating in this educational activity, participants should be able to: 1. Apply updated guidelines to assess
More informationMedication Policy Manual. Topic: Prolia, denosumab Date of Origin: August 11, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru223 Topic: Prolia, denosumab Date of Origin: August 11, 2010 Committee Approval Date: August 11,
More information